Weight gain over 4 months in schizophrenia patients: A comparison of olanzapine and risperidone

Schizophrenia Research

Volumn 49, Issue 3, 2001, Pages 261-267

  Ganguli, Rohan ^a   Brar, Jaspreet S ^a   Ayrton, Zenia ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Atypical antipsychotic; Body mass index; Olanzapine; Risperidone; Weight gain

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY MASS INDEX; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PIRENZEPINE; RISPERIDONE; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 0035971518     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(00)00080-3     Document Type: Article

References (26)

1. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., Weiden P.J. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry. 156:(11):1999;1686-1696.
2. Allison D.B., Fontaine K.R., Mentore J.L., Cappelleri J.C., Chandler L.P., Weiden P.J., Cheskin L.J. J. Clin. Psychiatry. 60:1999;215-220.
3. Beasley C.M., Tollefson G., Tran P., Satterlee W., Sanger T., Hamilton S. Olanzapine HGAD study group. Olanzapine versus placebo and haloperidol. Neuropsychopharmacology. 14:1996;111-123.
4. Beasley C.M., Hamilton S.H., Crawford A.M., Dellva M.A., Tollefson G.D., Tran P.V., Blin O., Beuzen J.N. Olanzapine versus haloperidol: Acute phase results of the international double-blind olanzapine trial. Eur. Neuropsychopharmacology. 7:1997;125-137.
5. Beasley C.M., Tollefson G.D., Tran P.V. Safety of olanzapine. J. Clin. Psychiatry. 58:(10):1997;13-17.
6. Bernstein J.G. Psychotropic drug induced weight gain: mechanism and management. Clin. Neuropsychopharmacology. 11:1988;S194-S206.
7. Brady K.T. Weight gain associated with psychotropic drugs. Southern Med. J. 82:1989;611-617.
8. Casey D.E. Side effect profiles of new antipsychotic agents. J. Clin. Psychiatry. 57:(11):1996;40-45.
9. Ceskova E., Svestka J. Double-blind comparison of risperidone and haloperidol in schizophrenia and schizoaffective psychoses. Pharmacopsychiatry. 26:1993;121-124.
10. Claus A., Bollen J., de Cuyper H., Eneman M., Malfroid M., Pueskens J., Heylen S. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: A multicenter double-blind comparative study. Acta Psych. Scand. 83:1992;295-305.
11. Daniel D.G., Goldberg T.E., Weinberger D.R., Kleinman J.E., Pickar D., Lubick L.J., Williams T.S. Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: A pilot study. Am. J. Psychiatry. 153:1996;417-419.
12. Doss F.W. The effect of antipsychotic drugs on body weight: A retrospective review. J. Clin. Psychiatry. 40:1979;528-530.
13. Garrattini S., Mennini T., Samanin R. Reduction of food intake by manipulation of central serotonin. Brit. J. Psychiatry. 155:(8):1989;S41-S51.
14. Gardos G., Cole J.O. Weight reduction in schizophrenics by molindone. Am. J. Psychiatry. 134:1977;302-304.
15. Holden J.M.C., Holden U.P. Weight changes with schizophrenic psychosis and psychotropic drug therapy. Psychosomatics. 9:1970;551-561.
16. Kraepelin E. Dementia Praecox and Paraphrenia. 1919;E. & S. Livinstone, Edinburgh.
17. Leadbetter R., Shutty M., Pavalonis D., Vieweg V., Higgins P., Downs M. Clozapiel-induced weight gain: Prevalence and clinical relevance. Am. J. Psychiatry. 149:1992;68-72.
18. Min S.K., Rhee C.S., Kim C., Kang D.Y. Risperidone versus haloperidol in the treatment of chronic schizophrenia patients: A parallel group double-blind comparative trial. Yonsei Med. J. 34:1993;179-196.
19. Nemeroff C.B. Dosing the antipsychotic medication olanzapine. J. Clin. Psychiatry. 58:(10):1997;45-49.
20. Clinical Guidelines on the Identification, Evaluation and Treatment of Overweight and Obesity in Adults. 1998;National Institute of Health, National Heart, Lung, and Blood Institute, MD.
21. Salomon M.S. Histamine: a new factor in control of feeding behavior. Diss. Abstracts. 53:(2B):1992;1102.
22. Stanton J.M. Weight gain associated with neuroleptic medication: A review. Schizophr. Bull. 21:1995;463-472.
23. Tran P.V., Hamilton S.H., Kuntz A.J., Potvin J.H., Anderson S.W., Beasley C.M., Tollefson G.D. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J. Clin. Psychopharmacology. 17:1997;407-418.
24. Umbricht D.S., Pollack S., Kane J.M. Clozapine and weight gain. J. Clin. Psychiatry. 55:(9):1994;157-160.
25. Wetterling T., Mubigbrodt H.E. Weight gain: side effect of atypical neuroleptics. J. Clin. Psychopharmacology. 19:1999;316-321.
26. Wirshing D.A., Wirshing W.C., Kyser L., Berisford M.A., Goldstein D., Pashdag J., Mintz J., Marder S.R. Novel anti-psychotics: comparison of weight gain liabilities. J. Clin. Psychiatry. 60:((6)):1999;358-363.